For information on this past event please contact Meetings Management

PROVISIONAL CONFERENCE PROGRAM

Wednesday 18th May 2005

08.55-09.00
Welcome and Opening Remarks
Virgil Schijns (Intervet BV, The Netherlands)

SESSION 1:
Immunological Mechanisms Underlying Adjuvant Activity
Moderator: Virgil Schijns (Intervet BV, The Netherlands)

09.00-09.20
‘Immunological mechanisms underlying vaccine adjuvant activity: Introductory overview’
Virgil Schijns (Intervet BV, The Netherlands)

09.20-09.50
‘Illuminating alum: Cellular studies of adjuvant induced responses’
Jim Brewer (University of Glasgow, UK)

09.50-10.20
‘IC31 – a potent type 1 inducing adjuvant and its mode of action’
Karen Lingnau et al. (Intercell AG, Vienna, Austria)

10.20-10.40
Coffee Break & Poster Set-Up

10.40-11.10
‘Dendritic cells as targets and tools for vaccines’
Filippo Belardelli (ISS, Rome, Italy)

11.10-11.30
‘TLR independent immunostimulatory activity of double stranded DNA: Implications for its roles in immune system and DNA vaccine immunogenicity’
Ken J. Ishii, C. Coban et al. (Japan Science & Technology Agency, Osaka University, Japan)

SESSION 2:
Host-Derived Immunopotentiators
Moderator: Filippo Bellardelli (ISS, Italy)

11.30-12.00
‘IFNs as vaccine adjuvants’
Enrico Proietti (ISS, Rome, Italy)

12.00-12.20
‘Multiple roles for the enhancement of the immune responses by C3d’
Franklin R. Toapanta and Ted M. Ross (University of Pittsburgh, Pennsylvania, USA)

12.20-12.40
‘A soluble LAG-3 protein as an immunostimulator for therapeutic vaccines’
F. Triebel (Immutep SA, Chatenay-Malabry, France)

12.40-13.00
‘RANTES/hemagglutinin fusion protein recruits immature dendritic cells and when delivered as a DNA vaccine by gene gun, stimulates antibody IFN-Y and IL-5 production to influenza virus more effectively than co-delivered plasmids or hemagglutinin plasmid alone’
M. Baird, S. Young, L. Slobbe, M. Wilson, J. Austyn, S. Preston and G. Buchan (University of Otago, Dunedin, New Zealand)

13.00-13.20
‘Reduced immunogenicity of a vaccine based on virus-like particles (VLP) containing CD154’
L. Giavedoni, S. Frey, M.S. Keckler, L Parodi, V. Hodara (Southwest Foundation for Biomedical Research, San Antonio, Texas, USA)

13.20-15.00
Lunch Break & Posters & Leisure Time for Delegates

SESSION 3:
Microbe-Derived Immunostimulants
Moderator: Luke O’Neill (Trinity College Dublin, Ireland)

15.00-15.30
‘TLR-dependent and TLR-independent pathways for adjuvant effect’
Kasper Hoebe (The Scripps Research Institute, La Jolla, California, USA)

15.30-16.00
‘Improving vaccine efficacy by exploiting the link between innate and adaptive immunity’
Jeff Powell and Carlo Russo (VaxInnate Corporation, New Jersey, USA)

16.00-16.30
‘Effective targeting of the innate immune response with next generation vaccine adjuvants’
Nicholas Valiante (Chiron Corporation, USA)

16.30-16.50
Tea Break & Posters

16.50-17.10
‘Toll-like receptor 9 mediates innate immune activation by malaria pigment hemozoin’
C. Coban, Ken J. Ishii et al. (Japan Science & Technology Agency, Osaka University, Japan)

17.10-17.30
‘Onchocerca volvulus activation-associated secreted protein-1 (OV-ASP-1) is a potent novel adjuvant for protein, polypeptide and peptide antigens’
Sara Lustigman (New York Blood Center, New York, USA)

17.30-17.50
‘Application of CpG-C class oligonucleotide and SUV liposome carrier to immunostimulatory oligonucleotide/protein complexes’
Gary Ott et al. (Dynavax Technologies, Berkley, California, USA)

17.50-18.10
‘Synthetic agonists of TLR9: Preclinical and clinical studies’
Ekambar Kandimalla, Timothy Sullivan and Sudhir Agrawal (Hybridon Inc., Cambridge, Massachusetts, USA)

18.15-19.15
Welcome Reception & Poster Session

19.15 onwards
Free Time for Delegates